Rituxan
rituximab · CD20-Directed Cytolytic Antibody
Indications & Uses
Non-Hodgkin lymphoma (diffuse large B-cell, follicular), chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide, and granulomatosis with polyangiitis.
Contraindications
None.
Side Effects & Warnings
Fatal infusion-related reactions, severe mucocutaneous reactions (Stevens-Johnson syndrome), hepatitis B virus reactivation, progressive multifocal leukoencephalopathy (PML), and tumor lysis syndrome.
Drug & Dietary Interactions
Renal toxicity observed when administered in combination with cisplatin.
Regulatory & Prescribing Information
FDA Approved Biologic (BLA 103705). Black Box Warning for Infusion Reactions, PML, and HBV Reactivation.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.